Welcome to our dedicated page for PTC Therapeutics news (Ticker: PTCT), a resource for investors and traders seeking the latest updates and insights on PTC Therapeutics stock.
PTC Therapeutics, Inc. (NASDAQ: PTCT) is a pioneering global biopharmaceutical company dedicated to discovering, developing, and commercializing orally-administered small-molecule therapeutics. The company is focused on post-transcriptional control processes in RNA biology, which are crucial for regulating protein synthesis and ensuring proper cellular function. PTC's innovative approach targets a range of therapeutic areas, including neuromuscular disorders, oncology, and infectious diseases, with a particular emphasis on treatments for orphan and ultra-orphan disorders.
One of PTC's notable achievements is the development of Translarna™ (ataluren), a treatment for nonsense mutation Duchenne muscular dystrophy (nmDMD). Despite a recent setback with the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) issuing a negative opinion, the European Commission has asked for a re-evaluation, keeping the medication available in Europe. This reflects the strong backing from the patient community and expert physicians who believe in its efficacy and safety.
The company’s robust product pipeline also includes Upstaza™ (eladocagene exuparvovec), a gene therapy for aromatic L-amino acid decarboxylase (AADC) deficiency. This therapy has recently been submitted for review by the U.S. FDA and granted Priority Review status. Upstaza has shown transformative clinical benefits in clinical trials and compassionate use programs, demonstrating significant neurological improvements in patients.
Additionally, PTC is advancing sepiapterin for the treatment of phenylketonuria (PKU). The company's Marketing Authorization Application (MAA) for sepiapterin has been accepted by the EMA, with submissions planned in the U.S., Brazil, and Japan. Sepiapterin has demonstrated significant reductions in blood phenylalanine levels, offering a potential new treatment option for PKU patients who currently have limited therapeutic choices.
Financially, PTC has shown strong revenue performance and is well-positioned for future success. Recent financial results indicate a thriving operational status, supported by a diversified portfolio and strategic partnerships. The company's commitment to providing best-in-class treatments for rare disorders, combined with its global commercial infrastructure, underscores its strategy to maximize value for all stakeholders.
PTC's mission is to leverage its scientific and clinical expertise to bring innovative therapies to patients in need, ensuring access to treatments that can significantly improve quality of life. For more information, please visit their official website.
PTC Therapeutics, Inc. (NASDAQ: PTCT) announced on January 5, 2023, the approval of non-statutory stock options for 39,585 shares and 13,045 restricted stock units (RSUs) for 33 new employees as a part of their employment compensation. This follows the NASDAQ inducement grant exception guidelines. The stock options have an exercise price of $39.42 per share, vesting over four years, while the RSUs also vest over a four-year period. These grants are designed to attract talent and align new hires’ interests with the company's long-term goals.
PTC Therapeutics reported a 2022 total revenue of approximately $710 million, showing over 30% year-over-year growth. The company projects 2023 total revenue guidance between $940 million and $1 billion. Significant corporate milestones include the approval of Upstaza™ for AADC deficiency and the initiation of several clinical trials. The unaudited net product revenue in 2022 reached $535 million, with guidance for DMD franchise revenue in 2023 between $545 million and $565 million.
PTC Therapeutics, based in South Plainfield, N.J., will present a company overview at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023, at 7:30 a.m. PST/10:30 a.m. EST.
The presentation can be accessed via a live webcast on the company’s Investor section and will be archived for 30 days. PTC focuses on developing medicines for rare disorders, aiming to provide access to transformative treatments for patients with unmet medical needs.
PTC Therapeutics (PTCT) announced that the Brazilian Health Regulatory Agency (ANVISA) has approved Waylivra™ (volanesorsen) as the first treatment for familial partial lipodystrophy (FPL) in Brazil. This marks a significant milestone as it's the first global approval for Waylivra for this indication. The approval was based on the Phase 2/3 BROADEN study, which demonstrated an 88% mean reduction in triglyceride levels for patients treated with Waylivra at three months, compared to only 22% for the placebo group. Waylivra is also approved for Familial Chylomicronemia Syndrome (FCS) in Brazil.
PTC Therapeutics has received authorization from the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK for Upstaza (eladocagene exuparvovec), the first gene therapy aimed at treating AADC deficiency. This rare disorder severely impacts motor development, posing life-threatening challenges. Upstaza has demonstrated clinical efficacy, allowing patients to achieve significant motor and cognitive milestones after treatment. This authorization follows a similar approval in the European Union, furthering PTC's commitment to innovative therapies for rare diseases.
PTC Therapeutics reported a 57% year-over-year revenue growth with total quarterly revenue of $217 million for Q3 2022. Key products: DMD revenue reached $131 million, with Translarna at $77 million and Emflaza at $55 million. The company secured strategic financing from Blackstone for up to $1 billion to support its pipeline. Despite growth, PTC recorded a net loss of $109.3 million and a significant decrease in cash equivalents to $288.4 million since 2021. Full-year revenue guidance increased to $710-$750 million.
PTC Therapeutics has entered a strategic financing collaboration with Blackstone, securing up to $500 million in funding to enhance its product pipeline and business development. This includes $350 million in low-cost capital at the close. The funds will help accelerate PTC's mission to deliver transformative medicines, with a goal of launching one therapy every 2-3 years. Blackstone's investment will be collateralized by PTC's existing products, including Translarna™ and Upstaza®. The collaboration aims to optimize capital structure and support new medicines.
PTC Therapeutics (NASDAQ: PTCT) has confirmed ongoing enrollment for its Phase 2 PIVOT-HD trial of PTC518, aimed at treating Huntington's disease. The 12-month study has received approval in several European countries and Australia, focusing on two dose levels: 5mg and 10mg. Enrollment began in the US but has paused due to FDA requests for additional data. There have been no treatment-related adverse events reported to date. PTC plans to share data from the initial 12-week study phase within the first half of 2023.
PTC Therapeutics, Inc. (NASDAQ: PTCT) will host a webcast conference call on October 27, 2022, at 4:30 p.m. ET to discuss its third quarter 2022 financial results and business updates. Participants can register for the call online to receive dial-in details and are advised to join 15 minutes early. A replay will be available approximately two hours after the call and can be accessed on the company's website for 30 days. PTC is focused on developing medicines for rare disorders, leveraging its scientific expertise and global commercial capabilities.
PTC Therapeutics, Inc. (NASDAQ: PTCT) announced it will present new data on Translarna™ (ataluren) at the 27th International Annual Congress of the World Muscle Society in Halifax, Nova Scotia, on October 12-14, 2022. Key presentations will highlight updated demographics and safety data, age at loss of ambulation, pulmonary function, and the efficacy of ataluren in patients with nonsense mutation Duchenne muscular dystrophy (nmDMD). Translarna is currently licensed in the European Economic Area for nmDMD treatment in ambulatory patients aged 2 and older, while being investigational in the U.S.
FAQ
What is the current stock price of PTC Therapeutics (PTCT)?
What is the market cap of PTC Therapeutics (PTCT)?
What is PTC Therapeutics focused on?
What is Translarna™ (ataluren)?
What is Upstaza™ (eladocagene exuparvovec)?
What is sepiapterin used for?
Where is PTC Therapeutics headquartered?
How does PTC Therapeutics generate revenue?
What is the company's strategy for growth?
What are some key products in PTC Therapeutics' pipeline?
What recent regulatory updates has PTC Therapeutics announced?
How can investors and media contact PTC Therapeutics?
